Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolving medical therapies for ulcerative colitis.

Russell D Cohen1

  • 1Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, MC 4076, 5841 South Maryland Avenue, Chicago, IL 60637, USA. rcohen@medicine.bsd.uchicago.edu

Current Gastroenterology Reports
|November 21, 2002
PubMed
Summary

New ulcerative colitis treatments offer improved efficacy and safety over older therapies. Emerging options like biologics and individualized approaches suggest a future of personalized ulcerative colitis management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients with Baseline Cardiovascular Risk.

The American journal of gastroenterology·2026
Same author

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

Digestive diseases and sciences·2026
Same author

Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease.

Clinical and translational science·2025
Same author

A positive <i>Clostridioides difficile</i> test does not impact outcomes in hospitalized patients with acute severe ulcerative colitis.

Therapeutic advances in gastroenterology·2025
Same author

Safety and Efficacy of Upadacitinib in Patients with Inflammatory Bowel Disease After Liver Transplantation: A Case Series.

Digestive diseases and sciences·2025
Same author

Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025

Area of Science:

  • Gastroenterology and Inflammatory Bowel Disease Research

Background:

  • Traditional ulcerative colitis (UC) therapies have historically shown limited efficacy and scope.
  • Recent advancements include novel mesalamine formulations and corticosteroids challenging older treatment paradigms.
  • The use of immunomodulatory agents like 6-mercaptopurine and azathioprine is established for refractory disease and remission maintenance.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for ulcerative colitis.
  • To highlight the potential of novel agents and individualized treatment approaches.

Main Methods:

  • Review of recent clinical studies and therapeutic advancements in ulcerative colitis management.
  • Analysis of efficacy, safety, and potential mechanisms of action for various treatment modalities.

Related Experiment Videos

Main Results:

  • New mesalamine and corticosteroid formulations demonstrate improved efficacy and safety profiles.
  • Biologic therapies targeting tumor necrosis factor, adhesion molecules, and cytokines are under investigation as potentially disease-altering treatments.
  • Investigational approaches include heparin, nicotine, and probiotics, indicating a trend towards personalized medicine.

Conclusions:

  • The therapeutic landscape for ulcerative colitis is rapidly evolving with new and promising options.
  • Future management of ulcerative colitis may necessitate individualized treatment strategies based on patient-specific factors.